Let's start with a penny. That's 10x from here and realistic in the near term given some of the catalysts re Magna, MANF, and 3CL. That would have the company at a $6.3M market cap. I mean why not? And why not a dime from there if the skies start clearing?

NOTE 8 – SUBSEQUENT EVENTS On May 2nd, 2023, Provista entered into Share Purchase Agreements with owners of 100% of the outstanding American Laboratory Services, Inc. (ALS), sole owner of NewStar Medical Laboratories LLC (NewStar) based in Kennesaw, GA to acquire all equity in ALS and NewStar. ALS shareholders represent leaders in the medical and business communities in the Atlanta, GA area and southeastern United States. NewStar is a CLIA/COLA-certified lab with over 14 innetwork laboratory service contracts with 7 out of the top 10 medical insurance companies, including Blue Cross & Blue Shield (BCBS), providing toxicology and proprietary specialized patient monitoring and drug drug interaction (DDI) diagnostic tools under the CareView brand to help physicians manage patients. Since closing, H. Swift Services, the largest former shareholder of ALS, has provided over $600,00 in working capital for Provista. Under the terms of the agreement at the Closing • ALS shareholders acquired 52.5% of the common shares of Provista, Todos retains 37.5% and Testing123 retains 10%. • Todos was issued $2,240,000 in Preferred Shares (Preferred), Testing123 was issued $385,000 and H. Swift Services was issued $105,000. • Testing123 and Provista amended its revolving line of credit facility to include NewStar Medical. • Todos maintains full ownership of to its proprietary Videssa, LymPro and TBIA diagnostic tests, and agrees to license to Provista the laboratory. developed test (LDT) rights to its proprietary diagnostic technologies in the United States. Provista agreed to share all relevant data with Todos allow for US FDA and ex-US regulatory submissions for approval as diagnostic test kits. Provista is responsible for all funding needed to launch Videssa, LymPro and TBIA. • Todos retains all revenue from clients prior to the agreement, and from sales representatives that predated the SPA. On May 26, 2023, Todos entered into a Master Supplier Agreement with Natural Partners, Inc. (dba FullScript) for the wholesale distribution of the dietary supplement Tollovid in the United States exclusively for the sale of products to the healthcare, health and wellness professionals. The Company retains full rights to sell through all retain and other non-healthcare, health and wellness wholesale distribution channels in the United States, and through all channels exUS.

Todos 10-k filed https://www.otcmarkets.com/otcapi/company/financial-report/376467/content

15-12G just filed. TOMDF going dark under rule 12g-4(a)(1)

when...how about if?

I wonder what Camelot Capital think of AMBS?

Mikhail, any one of the now hundreds of academic institutions studying MANF, Herantis, Todos, other pharma. Lots of options.

Good of you to remind the group about the criminal 'Joshua Sason and the $5M debt that's about to become unenforceable.

Acumen Diagnostics looks hungry to partner/acquire. Well-aligned and connected to Todos. We shall see. (she tagged GC)

https://www.linkedin.com/feed/update/urn:li:activity:7066794983911034880/

https://www.acumen-diagnostics.com/

what do you think about the revenue? $95k ain't nothing to sneeze at when that's about all you burn in a year.

That deal has been dead for like 9 months now... Company has been saying since last fall it is renegotiating with creditors. Did you see the filings yesterday? Magna boys officially going down. Should allow us to write off around $5m owed and maybe countersue(though probably nothing much left to go after and the line will be long). Simplifies creditor negotiations.

13d/a filed. Rob Rill has sold 72.8M shares since March 1. Now only 4% owner. Only has 78.6M shares left. He has been selling since .002 all the way to .008.

Fall 2021. The fatal decision not to pay off the convertibles. Mercy.

you might be right. and there's def bad paper on the books competeing ala Leviston and SIH. But an alternate view is right now that bad paper is clearing prior to a more important event. Not sure when it will turn.

update: not true...on ice

it's moronic because if they had stuck around until cash flow came in, they would have been paid, and kept their job. Instead, they have no job, didn't get paid, and are paying lawyers out of their pocket.

Two active court cases against Provista:
1:23-cv-00511-AT Debejare et al v. Provista Diagnostics, Inc. et al
where a former sales rep, former account support rep, former admin asst, former lab tech, former VP of sales and marketing, former lead assesioner, former specimen processor who all quit after not being paid between october 14th and november 23rd 2022.

This is a moronic lawsuit and these folks have hired a shit firm. Folks who aren't cut out for entrepreneurial ventures - sometimes you gotta wait to get paid. All claim they were working overtime, so business must have been good. Plaintiffs will all pay way more in legal fees than they will ever collect and the financial hit to the company even if they make it to a trial or settlement down the line. Looks like our expenses will have lessened by a bit. No impact to company.

1:22-cv-05134-MLB Jones v. Provista Diagnostics, Inc. et al
Same story as the above case, same attorney, but a single lab tech as the plaintiff. Importantly this lawsuit notes that all employees were not paid during this period of time, and that Provista starting paying employees again after this group quit. This is consistent with business being tight, and having to wait for payment of services as the holiday surge of testing came in.

So all in all, I'm not worried.

EMA Financial, where this dilution is occasionally generating, just settled with Cyber App CYAP. The tides are turning in favor of small caps.

Don might be that CEO. I want to invest before good things happen, not after.

Biggest MANF Research yet! "Given the hierarchical order from mitochondrial quality control failure for the eventual activation of proinflammatory cytokines in our deletion mutation mice, we envision that treatment with the upstream p-AMPK enhancer MANF, which can restore homeostasis of dysfunctional mitochondria, might be more effective in ADTKD-UMOD. MANF is an 18kD protein and recombinant MANF is readily available. In the future, we will continue to test the therapeutic application of MANF as a novel strategy for the treatment of ADTKD patients caused by various gene mutations. In addition, whether MANF can treat other proteinopathies resulting from mutant protein aggregates and altered proteostasis, such as Alzheimer’s disease amyotrophic lateral sclerosis and retinitis pigmentosa , is of great interest for the future investigation."

https://www.biorxiv.org/content/10.1101/2023.01.10.523171v1.full.pdf+html

If they do $5k tests a week through end of the year that's 35k tests, reimbursing avg $80 a pop for $2.8M Rev from Covid test alone. Conservative.

Add the Tollovid normal sales

Add specific Vending Revenue
Add lawsuit money from NOAH

Hoping for at least $4M Q4, but the ceiling could be $10-15M

I've not detected any changes in fundamentals. Still an incredible risk-reward opportunity. Think this is likely just short-term traders getting involved which means we should cap out around .006, but these events always diversify the shareholder base which always tightens shares available, so big moves are possible.

I checked the Magna case. We are due for a ruling any day now, but nothing posted yet. If that ruling posts against Magna, that would be a game-changer for AMBS.

no need to point this out each time. When the dam breaks and we do enter human trials, I will be sure to make that fact clear as day. One foot in front of the other. Each one of these trials is a step in the journey.

More new MANF research

MANF in hepatic fibrosis
https://www.sciencedirect.com/science/article/pii/S0753332222013208?via%3Dihub

No real application here, but interesting.
https://www.semanticscholar.org/paper/Hormonal-therapies-up-regulate-MANF-and-overcome-to-Zhang-Sun/643af4278b1a2789cb7833a5b23f85d914663d23

happened oct 17th too, big block sells. apparently no dilution. Could be a whale getting out over time. Could be a few fish getting out here and there. Stock recovers.

Waaaaaaaay more testing now than in 2008, each and every year the count and complexity grows, the publication count doesn't lie.

Fake news on the patents. Holding company owns these patents. I own a percent of the holding company, as do other investors.

$AMBS Another MANF Gene Therapy Article from Cambridge/Sweden/Belgium: Will you own this stock when the dam breaks?
"Conclusions
The results from this study indicate gene delivery of AAV8.ins-Manf prevents the development of diabetes in experimental T1D. The findings further indicate that expression of MANF in pancreatic beta-cells may have protective functions for survival and proliferation of beta-cells."
https://pdfs.semanticscholar.org/a569/9a5c6fc5fc66a65e80e15c9ca68b36728fde.pdf?_ga=2.16546038.1754799164.1667030756-972150293.1625338335

Bro has his family renting a modest 4bed 2 bath in an unimpressive suburb and does interviews in hoodies and the one good suit he bought 7 years ago.. You're telling lies about greed and theft.

What he did to shareholders? You mean never giving up? Any other CEO would have given up long ago, walked away, and there would be no chance of recovery. We still have a chance.

Note 9 – Subsequent Events On August 15, 2022, the Company received a notice from the Convertible Note Holders that the CRO VC had terminated discussions and was no longer interested in completing the transaction described in the Term Sheet. As a result, the Company and the Convertible Note Holders are currently negotiating a settlement of the convertible notes. On October 3, 2022, the Company received a termination notice from Psychogenics, Inc. with respect to the eltoprazine license agreement. The Company is currently evaluating its legal options.

Growing relationship with this organization out of British Columbia - something to watch
https://mylongcovidrelief.com/
https://www.linkedin.com/company/my-long-covid-relief/?viewAsMember=true

Shareholders aren't paying for any of these studies and we're not paying him to answer this question. We have invested now knowing that the damn will eventually break and we will benefit if we're still standing.

how many mice studies does it take to get to a phase I clinical trial

[owl]

Those NOAH scumbags:

10501 West Greenfield Avenue, ATTN: Payroll, West Allis, WI 53214

We're coming for that $4M

More MANF China research. in Septic Renal Injury and Colorectal Cancer. Gerald sharing a lot lately.

Conclusion: Mesencephalic astrocyte-derived neurotrophic factor has a certain protective effect on septic renal injury. Exogenous supplement of MANF can effectively alleviate the degree of renal injury after septic renal injury.

https://assets.researchsquare.com/files/rs-1886281/v1/d7812999-0217-4976-92b1-cc8118b50bc7.pdf?c=1663594677

More importantly, exogenous MANF significantly inhibited the migration of colon adenocarcinoma cells HCT116 and SW1116, but did not affect proliferation. Mechanistically, DLC1 reduced the retention of MANF in ER by competing the interaction between MANF and GRP78. Taken together, these data provided new insights into the suppressive effects of DLC1 on CRC, and revealed the potential of MANF in the treatment of CRC.

https://www.frontiersin.org/articles/10.3389/fonc.2022.900166/full

kudos to Mark for the discovery - some bum front company called RBG, owned by MaxLife Natural Products in Florida, which has knocked off Tollovid with something called Tollo19 and will be sued and dispensed with. But the more evil thing lurks beneath. Just like Florida set up pill mills in the 90's and 2000s it smells like there is a Long Covid scam clinic spree fixing to get set up with knock off tollovid. At least one business group in Miami looks like they were fixing to supply and distribute. And I have a feeling some of it's members are investors here and previously with AMBS.

$500M market cap definitely in the cards

Shares could be part of the compensation for influencers. I'm sure Irvin ain't cheap and Carl ain't either.

Carl's latest video with Tollovid up to 75k views now btw. That's probably more people who now know the brand than have discovered it in the last 2 years combined.

More MANF Research from China:

Increased serum concentrations of Mesencephalic astrocyte-derived neurotrophic factor in patients and rats with ischemic stroke

"MANF levels revealed a good value to diagnose TIA with area under the curve (AUC) of 0.949 (95% CI: 0.9093-0.9892)....Serum MANF levels correlate with neuroprotection, stroke severity, inflammation, and TIA recurrence."

J Stroke Cerebrovasc Dis
. 2022 Sep 7;31(11):106752. doi: 10.1016/j.jstrokecerebrovasdis.2022
The First Affiliated Hospital of Harbin Medical University

https://pubmed.ncbi.nlm.nih.gov/36087374/

i think the dilution suggests that while revenues are increasing, they are not increasing substantially/as quickly as needed.

O/S increase seems controlled. But concerning. I think they just juicing their cash to cover everything they're trying to do right now. Not ok. But also not a major threat.

Another kingcarlx tiktok. He's now directly putting the bottle and saying the product name in his more typical videos. which is getting more views. 27.5k views and 3k likes and counting

Grant Magers, Hempori CEO, was somehow involved in the Todos CBD factory deal. Bodes well for us.